Why carry out this study?

Pulmonary arterial hypertension (PAH) is a rare but incurable disease with considerable morbidity and mortality worldwide and in the USA.

Recent research and clinical guidelines suggest early intensification of PAH therapy with combination therapies.

Hospitalization is an important prognostic indicator for PAH progression, but little is known about treatment intensification coinciding with hospitalization.

What was learned from the study?

Results showed a majority of patients were prescribed monotherapy both before and after hospitalization, and a majority had no treatment intensification after hospitalization.

There is a need for more research to understand the reasons driving the gap between clinical practice and the evidence and guideline recommendations for initial combination therapies, as well as treatment intensification upon hospitalization.